Morgan Stanley upgraded Alvotech (ALVO) to Overweight from Equal Weight with a $14 price target The firm says the company’s “consistent” research and commercial progress provide visibility on its outlook and validation of its operating model. Alvotech’s “breadth” of commercial partners across geographies is a value driver for the shares, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO: